Korean Drug Statistics

Total Valuation

Korean Drug has a market cap or net worth of KRW 46.87 billion. The enterprise value is 17.91 billion.

Market Cap	46.87B
Enterprise Value	17.91B

Important Dates

The last earnings date was Thursday, November 27, 2025.

Earnings Date	Nov 27, 2025
Ex-Dividend Date	Dec 29, 2025

Share Statistics

Korean Drug has 10.91 million shares outstanding.

Current Share Class	10.91M
Shares Outstanding	10.91M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	50.60%
Owned by Institutions (%)	n/a
Float	5.39M

Valuation Ratios

The trailing PE ratio is 16.94.

PE Ratio	16.94
Forward PE	n/a
PS Ratio	0.75
PB Ratio	0.58
P/TBV Ratio	0.58
P/FCF Ratio	4.48
P/OCF Ratio	4.29
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.05, with an EV/FCF ratio of 1.71.

EV / Earnings	6.47
EV / Sales	0.29
EV / EBITDA	4.05
EV / EBIT	7.36
EV / FCF	1.71

Financial Position

The company has a current ratio of 7.25, with a Debt / Equity ratio of 0.00.

Current Ratio	7.25
Quick Ratio	5.34
Debt / Equity	0.00
Debt / EBITDA	0.02
Debt / FCF	0.01
Interest Coverage	491.43

Financial Efficiency

Return on equity (ROE) is 3.43% and return on invested capital (ROIC) is 1.88%.

Return on Equity (ROE)	3.43%
Return on Assets (ROA)	1.61%
Return on Invested Capital (ROIC)	1.88%
Return on Capital Employed (ROCE)	2.85%
Revenue Per Employee	230.42M
Profits Per Employee	10.25M
Employee Count	270
Asset Turnover	0.66
Inventory Turnover	1.77

Taxes

In the past 12 months, Korean Drug has paid 601.55 million in taxes.

Income Tax	601.55M
Effective Tax Rate	17.86%

Stock Price Statistics

The stock price has decreased by -1.72% in the last 52 weeks. The beta is 0.27, so Korean Drug's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	-1.72%
50-Day Moving Average	4,330.90
200-Day Moving Average	4,661.73
Relative Strength Index (RSI)	48.01
Average Volume (20 Days)	10,926

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Korean Drug had revenue of KRW 62.21 billion and earned 2.77 billion in profits.

Revenue	62.21B
Gross Profit	26.52B
Operating Income	2.43B
Pretax Income	3.37B
Net Income	2.77B
EBITDA	4.43B
EBIT	2.43B
Earnings Per Share (EPS)	n/a

Full Income Statement

Balance Sheet

The company has 29.03 billion in cash and 77.78 million in debt, giving a net cash position of 28.95 billion or 2,653.39 per share.

Cash & Cash Equivalents	29.03B
Total Debt	77.78M
Net Cash	28.95B
Net Cash Per Share	2,653.39
Equity (Book Value)	81.04B
Book Value Per Share	n/a
Working Capital	60.93B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 10.92 billion and capital expenditures -452.13 million, giving a free cash flow of 10.47 billion.

Operating Cash Flow	10.92B
Capital Expenditures	-452.13M
Free Cash Flow	10.47B
FCF Per Share	959.65

Full Cash Flow Statement

Margins

Gross margin is 42.62%, with operating and profit margins of 3.91% and 4.45%.

Gross Margin	42.62%
Operating Margin	3.91%
Pretax Margin	5.41%
Profit Margin	4.45%
EBITDA Margin	7.12%
EBIT Margin	3.91%
FCF Margin	16.83%

Dividends & Yields

This stock pays an annual dividend of 160.00, which amounts to a dividend yield of 3.73%.

Dividend Per Share	160.00
Dividend Yield	3.73%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	62.55%
Buyback Yield	n/a
Shareholder Yield	3.73%
Earnings Yield	5.90%
FCF Yield	22.34%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Korean Drug has an Altman Z-Score of 4.82 and a Piotroski F-Score of 5.

Altman Z-Score	4.82
Piotroski F-Score	5